Corporate Philosophy, Long-term Vision, Medium Term Business Plan

Long-Term Vision “Vision 110”

To embody our corporate philosophy—"Kyorin shall fulfill its social mission of contributing to better health by cherishing life"—the Group is pushing forward with our long-term vision, "Vision 110" (FY2023-2032), leading up to our 110th anniversary in 2033.Our envisioned goal is to become "a company that contributes broadly to people's health by positioning the innovative drug business—which continuously provides high-value new drugs that meet medical needs—as its core, while simultaneously developing a diverse range of health-related businesses." We are fully committed to taking the necessary steps to realize this vision.

Medium Term Business Plan
“Vision 110 -Stage 2-” (FY2026-FY2029)

The long-term vision, "Vision 110," is divided into three stages leading up to its final year (Stage 1: FY2023-2025; Stage 2: FY2026-2029; and Stage 3: FY2030-2032). Following the conclusion of the first phase, our medium-term business plan "Vision 110 -Stage 1-," in fiscal 2025, we have officially launched the new medium-term business plan, "Vision 110 -Stage 2-," as of fiscal 2026.

Materiality

To achieve our long-term vision “Vision 110,” which was formulated to realize our corporate philosophy, we consider it necessary to create both social value and economic value and, along with corporate growth, we place importance on contributing to the realization of a sustainable society.

Our initiatives to address sustainability issues are derived from our basic policy for sustainability and carried out, as appropriate, to address designated materialities (priority issues).